The 14 analysts offering 12-month price forecasts for Horizon Therapeutics PLC have a median target of 140.00, with a high estimate of 162.00 and a low estimate of 95.00. The median estimate represents a +73.20% increase from the last price of 80.83.
The current consensus among 14 polled investment analysts is to Buy stock in Horizon Therapeutics PLC. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $1.33
Reporting Date Aug 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.